Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized trial evaluating the effect of exemestane in clinical stage T1-3 N0-1 M0 postmenopausal breast cancer patients completing at least five years of tamoxifen therapy.

Next Previous
Search
Trial Profile

A randomized trial evaluating the effect of exemestane in clinical stage T1-3 N0-1 M0 postmenopausal breast cancer patients completing at least five years of tamoxifen therapy.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Exemestane (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer
  • Focus Therapeutic Use

Most Recent Events

  • 18 Apr 2011 The ClinicalTrials.gov record reports the completion date as 18 Apr 2011.
  • 16 Mar 2011 National Cancer Institute of Canada reports actual initiation date as 3 Jun 2002 and actual end date 9 Oct 2003.
  • 15 Aug 2009 Planned end date (Mar 2011) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top